+ Follow LOSARTAN Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 553385
[Title] => Price of hypertension, pneumonia cures slashed
[Summary] => Prices of medicines for the top two leading diseases in Central Visayas have been slashed by as much as fifty percent by the Department of Health in compliance with the Cheaper Medicines Law, making them more affordable and accessible to the people, Senator Mar Roxas said yesterday.
[DatePublished] => 2010-02-28 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Cebu News
[SectionUrl] => cebu-news
[URL] =>
)
[1] => Array
(
[ArticleID] => 292152
[Title] => Therapharma’s losartan brand marks first year
[Summary] => Therapharma, a unit of United Laboratories, recently celebrated the first year of its brand of losartan, a medicine for high blood pressure.
Losartan belongs to a new class of antihypertensive medicine called angiotensin receptor blocker (ARB).
According to Dr. Esperanza Cabral, past president of Philippine Society of Hypertension, several studies have shown that losartan is effective in lowering blood pressure and helps delay the onset of kidney problems.
Compared with other types of blood pressure medicines, losartan has lesser side effects of cough and rash.
[DatePublished] => 2005-08-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 273901
[Title] => Pharmacoeconomic ARB out in the market soon
[Summary] => High blood pressure is one of the most common medical conditions in the world today, but its treatment continues to be one of physicians’ greatest challenges.
Doctors and hypertensive patients welcome antihypertensive drugs which are effective, well-tolerated by the patients and are affordable.
Studies are now focused on the newer class of antihypertensive drugs such as the angiotensin receptor blockers (ARB).
[DatePublished] => 2005-04-14 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 262681
[Title] => Lessening stroke risk
[Summary] => High blood pressure remains the leading risk factor for stroke. Although stroke is multifactorial, reducing the blood pressure in a hypertensive individual is the single most important treatment strategy which can cut down the risk of developing a stroke. A stroke results in permanent damage to the brain tissue and in many cases, permanent disability for the patient.
This is the reason why there is a need for an antihypertensive drug which is not only effective in lowering the blood pressure but can also reduce other complications of hypertension.
[DatePublished] => 2004-08-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 252445
[Title] => Controlling hypertension
[Summary] => Nearly 700 million people in the world, including some 7.14 million Filipinos, are estimated to be suffering from high blood pressure, with many becoming permanently disabled or dying prematurely from its complications.
Adequate control of the blood pressure to optimal levels is very poor, especially in developing countries, with only nine percent of hypertensive Filipinos adequately controlled.
In 1999, hypertension was listed as a primary or contributing cause of death in about 50,000 of the more than 300,000 deaths in the Philippines.
[DatePublished] => 2004-06-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 139976
[Title] => 4-year medical study RENAAL shows permanent kidney damage risks can be reduced
[Summary] => • US Clinical Study shows "losartan" can help avoid
• Kidney Dialysis and Transplantation for millions suffering
• Type 2 Diabetes and Hypertension
According to a New England Journal of Medicine (NEJM) estimate, some 146 million people worldwide are afflicted with Type 2 diabetes, a common form of diabetes affecting 90 to 95 percent of patients with diabetes. The well-known malady usually occurs later in life and is often associated with increased body weight, hypertension and abnormalities of blood lipids.
[DatePublished] => 2001-11-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[6] => Array
(
[ArticleID] => 139409
[Title] => 4-year medical study RENAAL shows permanent kidney damage risks can be reduced
[Summary] => • US Clinical Study shows "losartan" can help avoid
• Kidney Dialysis and Transplantation for millions suffering
• Type 2 Diabetes and Hypertension
According to a New England Journal of Medicine (NEJM) estimate, some 146 million people worldwide are afflicted with Type 2 diabetes, a common form of diabetes affecting 90 to 95 percent of patients with diabetes. The well-known malady usually occurs later in life and is often associated with increased body weight, hypertension and abnormalities of blood lipids.
[DatePublished] => 2001-11-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[7] => Array
(
[ArticleID] => 138464
[Title] => Cost of end-stage renal disease reduced by losartan – new study
[Summary] => Losartan Improves Lives of Hypertensive Patients with Type 2 Diabetes and Kidney Disease by Reducing Need for Costly Dialysis and Transplantation Procedures, Resulting in Substantial Cost Savings
[DatePublished] => 2001-10-30 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[8] => Array
(
[ArticleID] => 137976
[Title] => Cost of end-stage renal disease reduced by losartan – new study
[Summary] => Losartan Improves Lives of Hypertensive Patients with Type 2 Diabetes and Kidney Disease by Reducing Need for Costly Dialysis and Transplantation Procedures, Resulting in Substantial Cost Savings
[DatePublished] => 2001-10-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[9] => Array
(
[ArticleID] => 135751
[Title] => Losartan significantly delays kidney disease, is excellent Cardio-Protector
[Summary] => Results from a new clinical trial show that treatment with the effective antihypertensive losartan (Cozaar) can protect the kidney and dramatically delay the progression of kidney disease, including reducing the risk of developing end-stage renal disease (ESRD).
[DatePublished] => 2001-10-05 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
LOSARTAN
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 553385
[Title] => Price of hypertension, pneumonia cures slashed
[Summary] => Prices of medicines for the top two leading diseases in Central Visayas have been slashed by as much as fifty percent by the Department of Health in compliance with the Cheaper Medicines Law, making them more affordable and accessible to the people, Senator Mar Roxas said yesterday.
[DatePublished] => 2010-02-28 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Cebu News
[SectionUrl] => cebu-news
[URL] =>
)
[1] => Array
(
[ArticleID] => 292152
[Title] => Therapharma’s losartan brand marks first year
[Summary] => Therapharma, a unit of United Laboratories, recently celebrated the first year of its brand of losartan, a medicine for high blood pressure.
Losartan belongs to a new class of antihypertensive medicine called angiotensin receptor blocker (ARB).
According to Dr. Esperanza Cabral, past president of Philippine Society of Hypertension, several studies have shown that losartan is effective in lowering blood pressure and helps delay the onset of kidney problems.
Compared with other types of blood pressure medicines, losartan has lesser side effects of cough and rash.
[DatePublished] => 2005-08-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 273901
[Title] => Pharmacoeconomic ARB out in the market soon
[Summary] => High blood pressure is one of the most common medical conditions in the world today, but its treatment continues to be one of physicians’ greatest challenges.
Doctors and hypertensive patients welcome antihypertensive drugs which are effective, well-tolerated by the patients and are affordable.
Studies are now focused on the newer class of antihypertensive drugs such as the angiotensin receptor blockers (ARB).
[DatePublished] => 2005-04-14 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 262681
[Title] => Lessening stroke risk
[Summary] => High blood pressure remains the leading risk factor for stroke. Although stroke is multifactorial, reducing the blood pressure in a hypertensive individual is the single most important treatment strategy which can cut down the risk of developing a stroke. A stroke results in permanent damage to the brain tissue and in many cases, permanent disability for the patient.
This is the reason why there is a need for an antihypertensive drug which is not only effective in lowering the blood pressure but can also reduce other complications of hypertension.
[DatePublished] => 2004-08-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 252445
[Title] => Controlling hypertension
[Summary] => Nearly 700 million people in the world, including some 7.14 million Filipinos, are estimated to be suffering from high blood pressure, with many becoming permanently disabled or dying prematurely from its complications.
Adequate control of the blood pressure to optimal levels is very poor, especially in developing countries, with only nine percent of hypertensive Filipinos adequately controlled.
In 1999, hypertension was listed as a primary or contributing cause of death in about 50,000 of the more than 300,000 deaths in the Philippines.
[DatePublished] => 2004-06-03 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 139976
[Title] => 4-year medical study RENAAL shows permanent kidney damage risks can be reduced
[Summary] => • US Clinical Study shows "losartan" can help avoid
• Kidney Dialysis and Transplantation for millions suffering
• Type 2 Diabetes and Hypertension
According to a New England Journal of Medicine (NEJM) estimate, some 146 million people worldwide are afflicted with Type 2 diabetes, a common form of diabetes affecting 90 to 95 percent of patients with diabetes. The well-known malady usually occurs later in life and is often associated with increased body weight, hypertension and abnormalities of blood lipids.
[DatePublished] => 2001-11-13 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[6] => Array
(
[ArticleID] => 139409
[Title] => 4-year medical study RENAAL shows permanent kidney damage risks can be reduced
[Summary] => • US Clinical Study shows "losartan" can help avoid
• Kidney Dialysis and Transplantation for millions suffering
• Type 2 Diabetes and Hypertension
According to a New England Journal of Medicine (NEJM) estimate, some 146 million people worldwide are afflicted with Type 2 diabetes, a common form of diabetes affecting 90 to 95 percent of patients with diabetes. The well-known malady usually occurs later in life and is often associated with increased body weight, hypertension and abnormalities of blood lipids.
[DatePublished] => 2001-11-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[7] => Array
(
[ArticleID] => 138464
[Title] => Cost of end-stage renal disease reduced by losartan – new study
[Summary] => Losartan Improves Lives of Hypertensive Patients with Type 2 Diabetes and Kidney Disease by Reducing Need for Costly Dialysis and Transplantation Procedures, Resulting in Substantial Cost Savings
[DatePublished] => 2001-10-30 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[8] => Array
(
[ArticleID] => 137976
[Title] => Cost of end-stage renal disease reduced by losartan – new study
[Summary] => Losartan Improves Lives of Hypertensive Patients with Type 2 Diabetes and Kidney Disease by Reducing Need for Costly Dialysis and Transplantation Procedures, Resulting in Substantial Cost Savings
[DatePublished] => 2001-10-26 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[9] => Array
(
[ArticleID] => 135751
[Title] => Losartan significantly delays kidney disease, is excellent Cardio-Protector
[Summary] => Results from a new clinical trial show that treatment with the effective antihypertensive losartan (Cozaar) can protect the kidney and dramatically delay the progression of kidney disease, including reducing the risk of developing end-stage renal disease (ESRD).
[DatePublished] => 2001-10-05 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
abtest
February 28, 2010 - 12:00am
August 18, 2005 - 12:00am
August 26, 2004 - 12:00am
November 13, 2001 - 12:00am
November 8, 2001 - 12:00am
October 30, 2001 - 12:00am
October 26, 2001 - 12:00am
October 5, 2001 - 12:00am
